Avacta reveals superior tumor-targeted drug delivery vs approved ADCs at Science Day 2026

Avacta Therapeutics presented new data at Science Day 2026 showing its pre|CISION® platform delivers cancer drugs more selectively and rapidly to tumors compared to approved antibody-drug conjugates (ADCs) like Enhertu® and Datroway®. Their AVA6103 program demonstrated faster tumor penetration and higher drug concentration, while AVA6207 showed improved dual payload delivery with better tumor response in models where conventional therapies failed. These advances highlight Avacta's potential to improve cancer treatment efficacy and reduce side effects, with plans to publish findings soon.